SEHK:2696Biotechs
A Look At Shanghai Henlius Biotech (SEHK:2696) Valuation After FDA Acceptance Of HANBEITAI Application
Shanghai Henlius Biotech (SEHK:2696) is back in focus after the US FDA accepted its biologics license application for HANBEITAI, covering multiple oncology indications across colorectal, lung, brain, kidney, ovarian and cervical cancers.
See our latest analysis for Shanghai Henlius Biotech.
The HANBEITAI filing comes after a period of strong market interest, with a 30 day share price return of 12.72%, year to date share price return of 16.47%, and a very large 1 year total shareholder return...